REGENXBIO Inc. Financing Cash Flow
REGENXBIO Inc. (RGNX) reported Financing Cash Flow of $3.93 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- REGENXBIO Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $17.57M, a 87.38% decline year-over-year.
- REGENXBIO Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$13.64M.
- REGENXBIO Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$9.58M.
- REGENXBIO Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$7.08M.
- REGENXBIO Inc. net cash provided by (used in) financing activities for fiscal 2025 was $116.77M, a 25.99% increase from fiscal 2024.
- REGENXBIO Inc. net cash provided by (used in) financing activities for fiscal 2024 was $92.68M.
- REGENXBIO Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$34.97M.
- REGENXBIO Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$28.84M, a 114.77% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.93M 10-Q · filed 2026-08-06 | -$5.65M derived: sum of 3 quarters · filed 2026-08-06 | -$12.73M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$13.64M 10-Q · filed 2026-05-14 | -$23.22M derived: sum of 2 quarters · filed 2026-05-14 | -$30.31M derived: sum of 3 quarters · filed 2026-05-14 | $108.93M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$9.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$16.67M derived: sum of 2 quarters · filed 2026-03-05 | $122.56M derived: sum of 3 quarters · filed 2026-08-06 | $116.77M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | -$7.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $132.15M derived: sum of 2 quarters · filed 2026-08-06 | $126.36M 10-Q · filed 2025-11-06 | $118.61M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $139.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $133.44M 10-Q · filed 2026-08-06 | $125.70M derived: sum of 3 quarters · filed 2026-08-06 | $114.84M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$5.79M 10-Q · filed 2026-05-14 | -$13.53M derived: sum of 2 quarters · filed 2026-05-14 | -$24.39M derived: sum of 3 quarters · filed 2026-05-14 | -$33.84M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | -$7.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$18.60M derived: sum of 2 quarters · filed 2026-03-05 | -$28.04M derived: sum of 3 quarters · filed 2026-03-05 | $92.68M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | -$10.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$20.30M derived: sum of 2 quarters · filed 2025-11-06 | $100.42M 10-Q · filed 2025-11-06 | $88.46M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$9.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $111.28M 10-Q · filed 2025-08-07 | $99.32M derived: sum of 3 quarters · filed 2025-08-07 | $94.51M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $120.72M 10-Q · filed 2025-05-12 | $108.76M derived: sum of 2 quarters · filed 2025-05-12 | $103.96M derived: sum of 3 quarters · filed 2025-05-12 | $94.80M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | -$11.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$16.77M derived: sum of 2 quarters · filed 2025-03-13 | -$25.93M derived: sum of 3 quarters · filed 2025-03-13 | -$34.97M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$13.97M derived: sum of 2 quarters · filed 2024-11-06 | -$23.00M 10-Q · filed 2024-11-06 | -$31.92M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2023-06-30 | -$9.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$18.20M 10-Q · filed 2024-08-01 | -$27.12M derived: sum of 3 quarters · filed 2025-03-13 | -$32.54M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2023-03-31 | -$9.04M 10-Q · filed 2024-05-08 | -$17.96M derived: sum of 2 quarters · filed 2025-03-13 | -$23.37M derived: sum of 3 quarters · filed 2025-03-13 | -$31.04M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2022-12-31 | -$8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$14.34M derived: sum of 2 quarters · filed 2025-03-13 | -$22.01M derived: sum of 3 quarters · filed 2025-03-13 | -$28.84M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | -$5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$13.09M derived: sum of 2 quarters · filed 2023-11-08 | -$19.92M 10-Q · filed 2023-11-08 | -$27.54M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-06-30 | -$7.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$14.50M 10-Q · filed 2023-08-02 | -$22.12M derived: sum of 3 quarters · filed 2024-02-27 | -$24.40M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2022-03-31 | -$6.83M 10-Q · filed 2023-05-03 | -$14.45M derived: sum of 2 quarters · filed 2024-02-27 | -$16.73M derived: sum of 3 quarters · filed 2024-02-27 | -$22.87M derived: sum of 4 quarters · filed 2024-02-27 | |||
| 2021-12-31 | -$7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$9.90M derived: sum of 2 quarters · filed 2024-02-27 | -$16.04M derived: sum of 3 quarters · filed 2024-02-27 | $195.25M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | -$2.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$8.42M derived: sum of 2 quarters · filed 2022-11-03 | $202.87M 10-Q · filed 2022-11-03 | $187.61M 10-Q · filed 2021-11-02 | $397.03M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | -$6.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $205.15M 10-Q · filed 2022-08-03 | $196.03M 10-Q · filed 2021-08-09 | $399.32M derived: sum of 3 quarters · filed 2023-02-28 | $400.78M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | $211.29M 10-Q · filed 2022-05-04 | $208.37M 10-Q · filed 2021-05-05 | $405.45M derived: sum of 2 quarters · filed 2023-02-28 | $406.91M derived: sum of 3 quarters · filed 2023-02-28 | $408.74M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2020-12-31 | $194.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $195.63M derived: sum of 2 quarters · filed 2023-02-28 | $197.45M derived: sum of 3 quarters · filed 2023-02-28 | $200.21M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $3.29M derived: sum of 2 quarters · filed 2021-11-02 | $6.05M 10-Q · filed 2021-11-02 | $7.59M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $1.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $4.59M 10-Q · filed 2021-08-09 | $6.13M derived: sum of 3 quarters · filed 2022-03-01 | $7.47M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $2.76M 10-Q · filed 2021-05-05 | $4.31M derived: sum of 2 quarters · filed 2022-03-01 | $5.64M derived: sum of 3 quarters · filed 2022-03-01 | $7.01M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.88M derived: sum of 2 quarters · filed 2022-03-01 | $4.25M derived: sum of 3 quarters · filed 2022-03-01 | $8.38M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $1.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.70M derived: sum of 2 quarters · filed 2020-11-04 | $6.83M 10-Q · filed 2020-11-04 | $12.12M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $5.49M 10-Q · filed 2020-08-06 | $10.78M derived: sum of 3 quarters · filed 2021-03-01 | $202.60M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | $4.13M 10-Q · filed 2020-05-07 | $9.41M derived: sum of 2 quarters · filed 2021-03-01 | $201.23M derived: sum of 3 quarters · filed 2021-03-01 | $204.40M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2018-12-31 | $5.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $197.10M derived: sum of 2 quarters · filed 2021-03-01 | $200.28M derived: sum of 3 quarters · filed 2021-03-01 | $204.44M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | $191.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $194.99M derived: sum of 2 quarters · filed 2019-11-05 | $199.16M 10-Q · filed 2019-11-05 | $200.90M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-06-30 | $3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $7.34M 10-Q · filed 2019-08-07 | $9.08M derived: sum of 3 quarters · filed 2020-02-26 | $9.69M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-03-31 | $4.17M 10-Q · filed 2019-05-07 | $5.91M derived: sum of 2 quarters · filed 2020-02-26 | $6.51M derived: sum of 3 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $2.35M derived: sum of 2 quarters · filed 2020-02-26 | $84.60M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $606.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $82.86M 10-Q · filed 2018-11-07 | |||||
| 2017-06-30 | $82.25M 10-Q · filed 2018-08-08 | ||||||
| 2016-12-31 | $119.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |